Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Sunday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial lowered their price objective on Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Fresenius Medical Care has an average rating of “Hold” and a consensus target price of $22.00.

Fresenius Medical Care Stock Performance

Shares of NYSE:FMS opened at $20.25 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The business’s 50 day moving average price is $19.56 and its 200-day moving average price is $19.93. The firm has a market capitalization of $11.88 billion, a PE ratio of 22.75, a P/E/G ratio of 1.09 and a beta of 0.90. Fresenius Medical Care has a 1 year low of $16.37 and a 1 year high of $22.87.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.38. The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. As a group, equities research analysts expect that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wulff Hansen & CO. boosted its stake in Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after buying an additional 325,439 shares during the last quarter. Triasima Portfolio Management inc. raised its position in Fresenius Medical Care by 27.4% in the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock valued at $1,631,000 after purchasing an additional 18,360 shares during the period. Corient Private Wealth LLC raised its position in Fresenius Medical Care by 164.6% in the fourth quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock valued at $1,378,000 after purchasing an additional 41,139 shares during the period. QRG Capital Management Inc. raised its position in Fresenius Medical Care by 10.9% in the second quarter. QRG Capital Management Inc. now owns 60,309 shares of the company’s stock valued at $1,151,000 after purchasing an additional 5,946 shares during the period. Finally, Veracity Capital LLC raised its position in Fresenius Medical Care by 172.2% in the first quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock valued at $1,022,000 after purchasing an additional 33,543 shares during the period. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.